- Conditions
- Psoriasis
- Interventions
- Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
- Drug
- Lead sponsor
- Centocor Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Graft vs. Host Disease
- Interventions
- Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Psoriasis
- Interventions
- ustekinumab, placebo
- Drug
- Lead sponsor
- Centocor Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 766 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,831 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more
- Conditions
- Axial Spondyloarthritis
- Interventions
- Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 11
- States / cities
- Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more
- Conditions
- Chronic Plaque Type Psoriasis
- Interventions
- AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 676 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
- Conditions
- Plaque Psoriasis
- Interventions
- Secukinumab, Ustekinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 123
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more
- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
- Conditions
- Axial Spondyloarthritis
- Interventions
- Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 19
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Abatacept, UST Placebo, ABA Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Guselkumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Trumbull, Connecticut • Clearwater, Florida + 9 more
- Conditions
- Plaque Psoriasis
- Interventions
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more